In April 2015, in partnership with the US Centers for Disease Control and Prevention and Gilead Sciences, the country of Georgia launched the world's first national HCV elimination programme, aiming to reduce HCV prevalence by 90% by 2020. After 2 years of progress, how can the Georgia experience inform global approaches to eliminating HCV?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The hepatitis C infection in Iran: a policy analysis of agenda-setting using Kingdon’s multiple streams framework
Health Research Policy and Systems Open Access 27 March 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
World Health Organization. Global health sector strategy on viral hepatitis, 2016–2021 (WHO, 2016).
World Health Organization. Global hepatitis report, 2017 (WHO, 2017).
Pawlotsky, J. M. et al. From non-A, non-B hepatitis to hepatitis C virus cure. J. Hepatol. 62, S87–99 (2015).
Ghinea, N. et al. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. Lancet 389, 1268–1272 (2016).
Gvinjilia, L. et al. National progress toward hepatitis C elimination — Georgia, 2015–2016. Morb. Mortal. Wkly Rep. 65, 1132–1135 (2016).
Walker, J. et al. Projected impact and pathways to success of the hepatitis C elimination program in Georgia, 2015–2020. J. Hepatol. 66, S63–S94 (2017).
Bourgeois, S. et al. Achieving WHO recommendations for hepatitis C virus elimination in Belgium. Acta Gastroenterol. Belg. 79, 222–226 (2016).
Gountas, I. et al. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence? The case of Greece. J. Gastroenterol. Hepatol. 32, 466–472 (2016).
National Academies of Sciences, Engineering, and Medicine. A national strategy for the elimination of hepatitis B and C: phase two report (The National Academies Press, 2017).
Scott, N. et al. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut http://dx.doi.org/10.1136/gutjnl-2016-311504, (2016).
Acknowledgements
The authors thank all clinicians participating in the Georgia HCV elimination programme, especially T. Tsertsvadze of the Infection Diseases, AIDS, and Clinical Immunology Research Center, Tbilisi, Georgia; M. Butsashvili, of Neolab, Tbilisi; D. Metreveli, of Medical Center Mrcheveli, Tbilisi; L. Sharvadze, of the Joint Georgian-French Hepatology Clinic Hepa, Tbilisi; I. Tskhomelidze and V. Kvaratskhelia of the Ministry of Labour, Health and Social Affairs of Georgia; D. Baliashvili, M. Tsereteli and M. Alkhazashvili of the National Center for Disease Control and Public Health of Georgia; J. Morgan, B. Skaggs, L. Gvinjilia and T. Kuchuloria of the South Caucasus Centers for Disease Control and Prevention Office, Tbilisi; and J. Drobeniuc, S. Shadaker, N. Glass, A. Koscelski, R. Wilson and J. Ward of the Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Partners of the Georgia HCV elimination programme are: Georgian Harm Reduction Network; WHO; Extension for Community Healthcare Outcomes, University of New Mexico; Liver Institute and Foundation for Education and Research; Foundation for Innovative Diagnostics; Médecins du Monde; Abbott Laboratories; Bristol University; Georgia State University; Global Fund; Becton Dickinson; Blood System Research Institute; Gilead Sciences.
The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the US Department of Health and Human Services.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table 1
Key activities for a nationwide HCV elimination program — Georgia (PDF 153 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Nasrullah, M., Sergeenko, D., Gamkrelidze, A. et al. HCV elimination — lessons learned from a small Eurasian country, Georgia. Nat Rev Gastroenterol Hepatol 14, 447–448 (2017). https://doi.org/10.1038/nrgastro.2017.100
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.100
This article is cited by
-
Breakthroughs in hepatitis C research: from discovery to cure
Nature Reviews Gastroenterology & Hepatology (2022)
-
The hepatitis C infection in Iran: a policy analysis of agenda-setting using Kingdon’s multiple streams framework
Health Research Policy and Systems (2019)
-
Hepatitis C elimination: a Public Health Perspective
Current Treatment Options in Gastroenterology (2019)